PureTech acquires LYT-100 to treat lymphedema
The candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms in pre-clinical studies.
Read More
Tag: small molecule candidate
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
